MedTrace Logo

An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis

NCT01741688 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2017-08-01

Study results available
· View outcomes & findings →

Summary

This observational study evaluates the use and efficacy of intravenous (IV) tocilizumab in routine clinical practice in participants with moderate to severe rheumatoid arthritis. Eligible participants initiated on tocilizumab treatment in accordance with the local label were followed for 6 months.

Conditions

Interventions

BIOLOGICAL

Tocilizumab

Tocilizumab was administered according to the local label.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-26
Primary Completion
2014-03-06
Completion
2014-03-06

Countries

  • Peru

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01741688 on ClinicalTrials.gov